|
US7655249B2
(en)
|
1998-09-30 |
2010-02-02 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US7063854B1
(en)
|
1998-09-30 |
2006-06-20 |
Corixa Corporation |
Composition and methods for WTI specific immunotherapy
|
|
US7901693B2
(en)
|
1998-09-30 |
2011-03-08 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US7115272B1
(en)
|
1998-09-30 |
2006-10-03 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US7144581B2
(en)
|
2000-10-09 |
2006-12-05 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US7329410B1
(en)
|
1998-09-30 |
2008-02-12 |
Corixa Corporation |
Compositions and method for WT1 specific immunotherapy
|
|
WO2001088197A2
(en)
*
|
2000-05-16 |
2001-11-22 |
Massachusetts Institute Of Technology |
Methods and compositions for interaction trap assays
|
|
US7029847B2
(en)
|
2000-05-16 |
2006-04-18 |
Massachusetts Institute Of Technology |
Methods and compositions for interaction trap assays
|
|
US7947469B2
(en)
*
|
2001-01-22 |
2011-05-24 |
Gendaq, Ltd. |
Modulation of HIV infection
|
|
EP1417344B1
(en)
*
|
2001-08-17 |
2011-06-15 |
Toolgen, Inc. |
Zinc finger domain libraries
|
|
US7553494B2
(en)
|
2001-08-24 |
2009-06-30 |
Corixa Corporation |
WT1 fusion proteins
|
|
EP1451297A4
(en)
*
|
2001-12-07 |
2006-06-28 |
Toolgen Inc |
PHENOTYPIC SCANNING OF CHIMERIC PROTEINS
|
|
US8799501B2
(en)
*
|
2002-04-30 |
2014-08-05 |
Hewlett-Packard Development Company, L. P. |
System and method for anonymously sharing and scoring information pointers, within a system for harvesting community knowledge
|
|
WO2003104414A2
(en)
*
|
2002-06-11 |
2003-12-18 |
The Scripps Research Institute |
Artificial transcription factors
|
|
AU2003260973A1
(en)
*
|
2002-09-05 |
2004-03-29 |
Toolgen, Inc. |
Bioinformatics analysis of cellular effects of artificial transcription factors
|
|
US20050032186A1
(en)
*
|
2002-12-09 |
2005-02-10 |
Kim Jin-Soo |
Regulatory zinc finger proteins
|
|
EP1631676A4
(en)
*
|
2003-06-10 |
2006-12-20 |
Toolgen Inc |
TRANSDUCIBLE DNA BINDING PROTEINS
|
|
EP3222715A1
(en)
|
2003-08-08 |
2017-09-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
US7407776B2
(en)
|
2003-09-19 |
2008-08-05 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
WO2005061705A1
(en)
*
|
2003-12-23 |
2005-07-07 |
Toolgen, Inc. |
Regulation of prokaryotic gene expression with zinc finger proteins
|
|
ES2315859T3
(es)
*
|
2004-04-08 |
2009-04-01 |
Sangamo Biosciences, Inc. |
Metodos y composiciones para tratar afecciones neuropaticas y neurodegenerativas.
|
|
KR100857125B1
(ko)
|
2004-05-25 |
2008-09-11 |
주식회사 툴젠 |
단일클론 항체 생산을 증가시키는 폴리펩타이드, 이를코드하는 핵산 및 이의 용도
|
|
AU2005287278B2
(en)
|
2004-09-16 |
2011-08-04 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
|
WO2007014275A2
(en)
|
2005-07-26 |
2007-02-01 |
Sangamo Biosciences, Inc. |
Targeted integration and expression of exogenous nucleic acid sequences
|
|
EP2447279B1
(en)
|
2006-05-25 |
2014-04-09 |
Sangamo BioSciences, Inc. |
Methods and compositions for gene inactivation
|
|
EP2213731B1
(en)
|
2006-05-25 |
2013-12-04 |
Sangamo BioSciences, Inc. |
Variant foki cleavage half-domains
|
|
WO2008021207A2
(en)
|
2006-08-11 |
2008-02-21 |
Dow Agrosciences Llc |
Zinc finger nuclease-mediated homologous recombination
|
|
KR100812110B1
(ko)
*
|
2006-10-24 |
2008-03-12 |
한국과학기술원 |
징크 핑거 단백질과 원핵 생물의 전사 인자를 포함하는인공 전사 인자의 제조 및 이의 이용
|
|
CA2667414C
(en)
|
2006-11-13 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the human glucocorticoid receptor locus
|
|
EP2092068B1
(en)
|
2006-12-14 |
2014-10-08 |
Dow AgroSciences LLC |
Optimized non-canonical zinc finger proteins
|
|
US8110379B2
(en)
|
2007-04-26 |
2012-02-07 |
Sangamo Biosciences, Inc. |
Targeted integration into the PPP1R12C locus
|
|
CA2692453C
(en)
|
2007-07-12 |
2018-01-09 |
Trevor Collingwood |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut8) gene expression
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
US20110014616A1
(en)
|
2009-06-30 |
2011-01-20 |
Sangamo Biosciences, Inc. |
Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
|
|
ES2585157T3
(es)
|
2007-09-27 |
2016-10-04 |
Dow Agrosciences Llc |
Proteínas de dedo de cinc de diseño que se dirigen a los genes de 5-enolpiruvil shikimato-3-fosfato sintasa
|
|
EP2188384B1
(en)
|
2007-09-27 |
2015-07-15 |
Sangamo BioSciences, Inc. |
Rapid in vivo identification of biologically active nucleases
|
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
|
AU2008317354B2
(en)
|
2007-10-25 |
2014-04-10 |
Ospedale San Raffaele S.R.L. |
Methods and compositions for targeted integration
|
|
WO2009131632A1
(en)
|
2008-04-14 |
2009-10-29 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
|
PL2274430T3
(pl)
|
2008-04-30 |
2017-09-29 |
Sanbio Inc |
Komórki regenerujące nerwy ze zmianami w metylacji DNA
|
|
EP2297318B1
(en)
|
2008-05-28 |
2018-05-23 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
KR101794638B1
(ko)
|
2008-06-10 |
2017-12-04 |
상가모 테라퓨틱스, 인코포레이티드 |
Ｂａｘ- 및 ｂａｋ-결함 세포주들의 제조 방법 및 조성물
|
|
KR20160015400A
(ko)
|
2008-08-22 |
2016-02-12 |
상가모 바이오사이언스 인코포레이티드 |
표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
|
|
CA2741119C
(en)
|
2008-10-29 |
2019-02-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating glutamine synthetase gene expression
|
|
CN102625655B
(zh)
|
2008-12-04 |
2016-07-06 |
桑格摩生物科学股份有限公司 |
使用锌指核酸酶在大鼠中进行基因组编辑
|
|
SI2370575T1
(en)
|
2008-12-17 |
2018-07-31 |
Dow Agrosciences, Llc |
Targeted integration in the Zp15 locus
|
|
CA2934285C
(en)
|
2009-02-04 |
2018-11-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
|
CA2755192C
(en)
|
2009-03-20 |
2018-09-11 |
Sangamo Biosciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
|
US9834787B2
(en)
|
2009-04-09 |
2017-12-05 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
CA2769262C
(en)
|
2009-07-28 |
2019-04-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating trinucleotide repeat disorders
|
|
NZ598457A
(en)
|
2009-08-03 |
2014-06-27 |
Recombinetics Inc |
Methods and compositions for targeted gene modification
|
|
KR20170125406A
(ko)
|
2009-08-11 |
2017-11-14 |
상가모 테라퓨틱스, 인코포레이티드 |
표적화 변형에 대한 동형접합성 유기체
|
|
RU2712833C2
(ru)
|
2009-10-22 |
2020-01-31 |
ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи |
Конструируемые белки с цинковыми пальцами, направленные на гены растений, вовлеченные в биосинтез жирных кислот
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
EP2526112B1
(en)
|
2010-01-22 |
2018-10-17 |
Dow AgroSciences LLC |
Targeted genomic alteration
|
|
FR2955480B1
(fr)
|
2010-01-26 |
2012-01-06 |
Christian Choux |
Dispositif d'osteosynthese de la paroi thoracique
|
|
ES2751916T3
(es)
|
2010-02-08 |
2020-04-02 |
Sangamo Therapeutics Inc |
Semidominios de escisión genomanipulados
|
|
WO2011100058A1
(en)
|
2010-02-09 |
2011-08-18 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
PL2566972T3
(pl)
|
2010-05-03 |
2020-06-29 |
Sangamo Therapeutics, Inc. |
Kompozycje do wiązania modułów z motywem palca cynkowego
|
|
CA2798988C
(en)
|
2010-05-17 |
2020-03-10 |
Sangamo Biosciences, Inc. |
Tal-effector (tale) dna-binding polypeptides and uses thereof
|
|
CA2805442C
(en)
|
2010-07-21 |
2020-05-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of an hla locus
|
|
AU2011312562B2
(en)
|
2010-09-27 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
|
WO2012051343A1
(en)
|
2010-10-12 |
2012-04-19 |
The Children's Hospital Of Philadelphia |
Methods and compositions for treating hemophilia b
|
|
WO2012094132A1
(en)
*
|
2011-01-05 |
2012-07-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
|
WO2012139045A1
(en)
|
2011-04-08 |
2012-10-11 |
Gilead Biologics, Inc. |
Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
|
|
WO2013016446A2
(en)
|
2011-07-25 |
2013-01-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
CA3186126A1
(en)
|
2011-09-21 |
2013-03-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
|
MA36970A1
(fr)
*
|
2011-10-11 |
2016-03-31 |
Aliophtha Ag |
Régulation de l'expression d'un récepteur par l'intermédiaire de l'administration de facteurs de transcription artificiels
|
|
CA2852955C
(en)
|
2011-10-27 |
2021-02-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
HK1200871A1
(en)
|
2011-11-16 |
2015-08-14 |
Sangamo Therapeutics, Inc. |
Modified dna-binding proteins and uses thereof
|
|
JP6023218B2
(ja)
|
2012-01-27 |
2016-11-09 |
サンバイオ，インコーポレイティド |
血管新生及び血管発生を調節するための方法及び組成物
|
|
BR112014021104B1
(pt)
|
2012-02-29 |
2023-03-28 |
Sangamo Biosciences, Inc |
Proteína de fusão de ocorrência não natural compreendendo um domínio de ligação de dna de dedo de zinco manipulado que se liga a um gene htt, seu uso, método in vitro de modificação da expressão de um gene htt em uma célula, e método de geração de um sistema modelo para o estudo da doença de huntington
|
|
CN102634535B
(zh)
*
|
2012-04-12 |
2014-11-26 |
西北农林科技大学 |
一种基于锌指蛋白插入载体的随机锌指蛋白库的构建方法
|
|
UA115875C2
(uk)
|
2012-05-02 |
2018-01-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Рослина помідора зі зменшеною активністю малатдегідрогенази та спосіб її отримання
|
|
BR112014027813A2
(pt)
|
2012-05-07 |
2017-08-08 |
Dow Agrosciences Llc |
métodos e composições para integração de transgenes direcionada mediada por nuclease
|
|
WO2014011901A2
(en)
|
2012-07-11 |
2014-01-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
ES2697912T3
(es)
|
2012-07-11 |
2019-01-29 |
Sangamo Therapeutics Inc |
Métodos y composiciones para el tratamiento de enfermedades monogénicas
|
|
AU2013308770B2
(en)
|
2012-08-29 |
2019-01-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
CA2884162C
(en)
|
2012-09-07 |
2020-12-29 |
Dow Agrosciences Llc |
Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
|
UA119135C2
(uk)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб отримання трансгенної рослини
|
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
|
ES2824024T3
(es)
|
2012-10-10 |
2021-05-11 |
Sangamo Therapeutics Inc |
Compuestos modificadores de células T y usos de los mismos
|
|
AU2013355327A1
(en)
|
2012-12-05 |
2015-06-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
US20140173783A1
(en)
|
2012-12-13 |
2014-06-19 |
Dow Agrosciences Llc |
Precision gene targeting to a particular locus in maize
|
|
CA2901676C
(en)
|
2013-02-25 |
2023-08-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
EP2975942B1
(en)
|
2013-03-21 |
2018-08-08 |
Sangamo Therapeutics, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
WO2014165612A2
(en)
|
2013-04-05 |
2014-10-09 |
Dow Agrosciences Llc |
Methods and compositions for integration of an exogenous sequence within the genome of plants
|
|
AU2014265331B2
(en)
|
2013-05-15 |
2019-12-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
WO2015031619A1
(en)
|
2013-08-28 |
2015-03-05 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
WO2015057976A1
(en)
|
2013-10-17 |
2015-04-23 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
US9957526B2
(en)
|
2013-10-17 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
EP3862434A1
(en)
|
2013-11-04 |
2021-08-11 |
Dow AgroSciences LLC |
Optimal soybean loci
|
|
BR102014027442B1
(pt)
|
2013-11-04 |
2022-09-27 |
Dow Agrosciences Llc |
Molécula de ácido nucleico recombinante, uso de uma planta de milho, parte de planta de milho ou célula de planta de milho compreendendo a mesma e método para produzir uma célula vegetal transgênica compreendendo um dna de interesse
|
|
WO2015066638A2
(en)
|
2013-11-04 |
2015-05-07 |
Dow Agrosciences Llc |
Optimal maize loci
|
|
US10233465B2
(en)
|
2013-11-04 |
2019-03-19 |
Dow Agrosciences Llc |
Optimal soybean loci
|
|
CN105934524A
(zh)
|
2013-11-11 |
2016-09-07 |
桑格摩生物科学股份有限公司 |
用于治疗亨廷顿氏病的方法和组合物
|
|
DK3492593T3
(da)
|
2013-11-13 |
2021-11-08 |
Childrens Medical Center |
Nukleasemedieret regulering af genekspression
|
|
EP3757116A1
(en)
|
2013-12-09 |
2020-12-30 |
Sangamo Therapeutics, Inc. |
Methods and compositions for genome engineering
|
|
JP6606088B2
(ja)
|
2014-02-24 |
2019-11-13 |
サンガモ セラピューティクス， インコーポレイテッド |
ヌクレアーゼ媒介性標的化組み込みのための方法および組成物
|
|
AU2015231353B2
(en)
|
2014-03-18 |
2020-11-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
|
WO2015164748A1
(en)
|
2014-04-24 |
2015-10-29 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (tale) proteins
|
|
RU2691102C2
(ru)
|
2014-05-08 |
2019-06-11 |
Сангамо Байосайенсиз, Инк. |
Способы и композиции для лечения болезни хантингтона
|
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
|
EP3152319A4
(en)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for nuclease design
|
|
EP3166964A1
(en)
|
2014-07-08 |
2017-05-17 |
Vib Vzw |
Means and methods to increase plant yield
|
|
BR112017000925B1
(pt)
|
2014-07-14 |
2023-10-10 |
Washington State University |
Método de reprodução de porcos, método para gerar um porco sem nenhuma célula espermatogônica funcional, método de produção de um macho receptor e método de produção de porcos
|
|
WO2016011381A1
(en)
|
2014-07-18 |
2016-01-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells
|
|
US9757420B2
(en)
|
2014-07-25 |
2017-09-12 |
Sangamo Therapeutics, Inc. |
Gene editing for HIV gene therapy
|
|
US9816074B2
(en)
|
2014-07-25 |
2017-11-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
CN106795488B
(zh)
|
2014-09-16 |
2021-03-30 |
桑格摩治疗股份有限公司 |
用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
EP3247366A4
(en)
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
EP4335918A3
(en)
|
2015-04-03 |
2024-04-17 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
KR20170141217A
(ko)
|
2015-05-12 |
2017-12-22 |
상가모 테라퓨틱스, 인코포레이티드 |
유전자 발현의 뉴클레아제-매개된 조절
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
WO2017011519A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
BR112018002417A2
(pt)
|
2015-08-06 |
2018-09-18 |
Univ Missouri |
animal não humano ou descendente do mesmo ou uma célula de animal, animal suíno, descendente ou célula, célula, descendente, método de reprodução, população de animais, método para aumentar uma resistência de animal, molécula de ácido nucleico, ácido nucleico e ácido nucleico isolado
|
|
SI3352776T1
(sl)
|
2015-09-23 |
2025-08-29 |
Sangamo Therapeutics, Inc. |
Represorji Htt in njihove uporabe
|
|
AU2016361350B2
(en)
|
2015-11-23 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
CN108699132B
(zh)
|
2015-12-18 |
2023-08-11 |
桑格摩生物治疗股份有限公司 |
Mhc细胞受体的靶向破坏
|
|
ES2983043T3
(es)
|
2015-12-18 |
2024-10-21 |
Sangamo Therapeutics Inc |
Alteración dirigida del receptor de células T
|
|
EP3402533B1
(en)
|
2016-01-15 |
2021-08-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
US10724020B2
(en)
|
2016-02-02 |
2020-07-28 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
|
US11421218B2
(en)
|
2016-03-23 |
2022-08-23 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
|
CA3030783A1
(en)
|
2016-07-13 |
2018-01-18 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
CN114652735A
(zh)
|
2016-07-27 |
2022-06-24 |
凯斯西储大学 |
促进髓鞘形成的化合物和方法
|
|
WO2018029034A1
(en)
|
2016-08-09 |
2018-02-15 |
Vib Vzw |
Cellulose synthase inhibitors and mutant plants
|
|
US10975393B2
(en)
|
2016-08-24 |
2021-04-13 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
|
SG11201901531TA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Regulation of gene expression using engineered nucleases
|
|
US10960085B2
(en)
|
2016-09-07 |
2021-03-30 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
AU2017338827B2
(en)
|
2016-10-03 |
2023-08-31 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
|
JP6887492B6
(ja)
|
2016-10-04 |
2021-07-14 |
プレシジョン バイオサイエンシズ，インク． |
遺伝子改変細胞で使用するための共刺激ドメイン
|
|
AU2017345430B2
(en)
|
2016-10-20 |
2024-09-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of Fabry disease
|
|
JP7108608B2
(ja)
|
2016-10-31 |
2022-07-28 |
サンガモ セラピューティクス， インコーポレイテッド |
造血幹細胞および前駆細胞におけるｓｃｉｄ関連遺伝子の遺伝子修正
|
|
MX2019006426A
(es)
|
2016-12-01 |
2019-08-14 |
Sangamo Therapeutics Inc |
Reguladores de tau, y composiciones y metodos para su administracion.
|
|
MA49610A
(fr)
|
2016-12-08 |
2020-05-27 |
Univ Case Western Reserve |
Procédés et compositions pour améliorer la production de myéline fonctionnelle
|
|
WO2018195418A1
(en)
|
2017-04-20 |
2018-10-25 |
Oregon Health & Science University |
Human gene correction
|
|
CN110869497A
(zh)
|
2017-05-03 |
2020-03-06 |
桑格摩生物治疗股份有限公司 |
修饰囊性纤维化跨膜传导调节蛋白（cftr）基因的方法和组合物
|
|
WO2018208837A1
(en)
|
2017-05-08 |
2018-11-15 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
AU2018292526A1
(en)
|
2017-06-30 |
2020-01-16 |
Precision Biosciences, Inc. |
Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
|
|
WO2019070856A1
(en)
|
2017-10-03 |
2019-04-11 |
Precision Biosciences, Inc. |
MODIFIED EPIDERMAL GROWTH FACTOR RECEPTOR PEPTIDES FOR USE IN GENETICALLY MODIFIED CELLS
|
|
WO2019070541A1
(en)
|
2017-10-03 |
2019-04-11 |
Juno Therapeutics, Inc. |
HPV-SPECIFIC BINDING MOLECULES
|
|
US20200299658A1
(en)
|
2017-11-01 |
2020-09-24 |
Precision Biosciences, Inc. |
Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
|
|
CN111565730B
(zh)
|
2017-11-09 |
2024-09-17 |
桑格摩生物治疗股份有限公司 |
细胞因子诱导型含sh2蛋白（cish）基因的遗传修饰
|
|
CN111727259B
(zh)
|
2017-12-01 |
2024-04-19 |
编码治疗公司 |
工程化的dna结合蛋白
|
|
CA3084572A1
(en)
|
2017-12-18 |
2019-06-27 |
Syngenta Participations Ag |
Targeted insertion sites in the maize genome
|
|
CN111741955B
(zh)
|
2018-01-17 |
2024-02-23 |
沃泰克斯药物股份有限公司 |
Dna-pk抑制剂
|
|
EP3740480B1
(en)
|
2018-01-17 |
2024-03-06 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
|
JP7483612B2
(ja)
|
2018-01-17 |
2024-05-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ゲノム編集効率を増加するためのキノキサリノン化合物、組成物、方法、およびキット
|
|
JP7275152B2
(ja)
|
2018-02-08 |
2023-05-17 |
サンガモ セラピューティクス， インコーポレイテッド |
操作された標的特異的なヌクレアーゼ
|
|
MA52656A
(fr)
|
2018-04-05 |
2021-02-17 |
Editas Medicine Inc |
Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
|
|
RU2020135968A
(ru)
|
2018-04-05 |
2022-05-06 |
Джуно Терапьютикс, Инк. |
T-клеточные рецепторы и модифицированные клетки, экспрессирующие
|
|
SG11202009446TA
(en)
|
2018-04-05 |
2020-10-29 |
Juno Therapeutics Inc |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2019204457A1
(en)
|
2018-04-18 |
2019-10-24 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (htt)
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
JP7541508B2
(ja)
|
2018-08-23 |
2024-08-28 |
サンガモ セラピューティクス， インコーポレイテッド |
操作された標的特異的な塩基エディター
|
|
WO2020061161A1
(en)
|
2018-09-18 |
2020-03-26 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (pd1) specific nucleases
|
|
EP3852911B1
(en)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
CN113226333A
(zh)
|
2018-10-02 |
2021-08-06 |
桑格摩生物治疗股份有限公司 |
用于调控Tau蛋白的方法和组合物
|
|
EP3898661A1
(en)
|
2018-12-21 |
2021-10-27 |
Precision BioSciences, Inc. |
Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
|
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
JP2022519410A
(ja)
|
2019-02-06 |
2022-03-24 |
サンガモ セラピューティクス， インコーポレイテッド |
ムコ多糖症ｉ型の処置のための方法
|
|
CA3132167A1
(en)
|
2019-04-02 |
2020-10-08 |
Weston P. MILLER IV |
Methods for the treatment of beta-thalassemia
|
|
CN116200342A
(zh)
|
2019-04-03 |
2023-06-02 |
精密生物科学公司 |
包含microRNA适应的shRNA（shRNAmiR）的遗传修饰的免疫细胞
|
|
WO2020206231A1
(en)
|
2019-04-05 |
2020-10-08 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
PE20212332A1
(es)
|
2019-04-23 |
2021-12-14 |
Sangamo Therapeutics Inc |
Moduladores de la expresioon del gen de marco de lectura abierto 72 del cromosoma 9 y usos de los mismos
|
|
KR20220016474A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 ｃｄ247 유전자 자리로부터 키메라 수용체를 발현하는 세포, 관련 폴리뉴클레오타이드 및 방법
|
|
BR112021021075A2
(pt)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
|
|
EP4004216A1
(en)
|
2019-07-25 |
2022-06-01 |
Precision BioSciences, Inc. |
Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
|
|
WO2021035054A1
(en)
|
2019-08-20 |
2021-02-25 |
Precision Biosciences, Inc. |
Lymphodepletion dosing regimens for cellular immunotherapies
|
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CN114728037A
(zh)
|
2019-10-02 |
2022-07-08 |
桑格摩生物治疗股份有限公司 |
用于朊病毒病治疗的锌指蛋白转录因子
|
|
AU2020356962A1
(en)
|
2019-10-02 |
2022-04-14 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for repressing alpha-synuclein expression
|
|
WO2021087305A1
(en)
|
2019-10-30 |
2021-05-06 |
Precision Biosciences, Inc. |
Cd20 chimeric antigen receptors and methods of use for immunotherapy
|
|
TW202132565A
(zh)
|
2019-11-01 |
2021-09-01 |
美商聖加莫治療股份有限公司 |
Ｇｉｎ重組酶變異體
|
|
WO2021113543A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
|
|
CN115210251A
(zh)
|
2020-01-22 |
2022-10-18 |
桑格摩生物治疗股份有限公司 |
用于阻遏tau表达的锌指蛋白转录因子
|
|
WO2021158915A1
(en)
|
2020-02-06 |
2021-08-12 |
Precision Biosciences, Inc. |
Recombinant adeno-associated virus compositions and methods for producing and using the same
|
|
US20230263121A1
(en)
|
2020-03-31 |
2023-08-24 |
Elo Life Systems |
Modulation of endogenous mogroside pathway genes in watermelon and other cucurbits
|
|
US20230279440A1
(en)
|
2020-05-06 |
2023-09-07 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
|
WO2021224395A1
(en)
|
2020-05-06 |
2021-11-11 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
|
WO2021231259A1
(en)
|
2020-05-11 |
2021-11-18 |
Precision Biosciences, Inc. |
Self-limiting viral vectors encoding nucleases
|
|
EP4150057A2
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
MX2023000614A
(es)
|
2020-07-16 |
2023-02-13 |
Acuitas Therapeutics Inc |
Lipidos cationicos para usarse en nanoparticulas lipidicas.
|
|
EP4192875A1
(en)
|
2020-08-10 |
2023-06-14 |
Precision BioSciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
|
US12152251B2
(en)
|
2020-08-25 |
2024-11-26 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
EP4217479A1
(en)
|
2020-09-25 |
2023-08-02 |
Sangamo Therapeutics, Inc. |
Zinc finger fusion proteins for nucleobase editing
|
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
US20240060079A1
(en)
|
2020-10-23 |
2024-02-22 |
Elo Life Systems |
Methods for producing vanilla plants with improved flavor and agronomic production
|
|
KR20230090367A
(ko)
|
2020-11-04 |
2023-06-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
|
|
EP4243609A1
(en)
|
2020-11-16 |
2023-09-20 |
Pig Improvement Company UK Limited |
Influenza a-resistant animals having edited anp32 genes
|
|
US20250127811A1
(en)
|
2021-01-28 |
2025-04-24 |
Precision Biosciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
|
WO2022226316A1
(en)
|
2021-04-22 |
2022-10-27 |
Precision Biosciences, Inc. |
Compositions and methods for generating male sterile plants
|
|
WO2023064872A1
(en)
|
2021-10-14 |
2023-04-20 |
Precision Biosciences, Inc. |
Combinations of anti-bcma car t cells and gamma secretase inhibitors
|
|
EP4419111A1
(en)
|
2021-10-19 |
2024-08-28 |
Precision Biosciences, Inc. |
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023091910A1
(en)
|
2021-11-16 |
2023-05-25 |
Precision Biosciences, Inc. |
Methods for cancer immunotherapy
|
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
|
IL313486A
(en)
|
2021-12-16 |
2024-08-01 |
Acuitas Therapeutics Inc |
Lipids for use in lipid nanoparticle formulations
|
|
IL313758A
(en)
|
2021-12-22 |
2024-08-01 |
Sangamo Therapeutics Inc |
Novel zinc finger fusion proteins for nuclear base editing
|
|
EP4460571A1
(en)
|
2022-01-05 |
2024-11-13 |
Vib Vzw |
Means and methods to increase abiotic stress tolerance in plants
|
|
WO2023131637A1
(en)
|
2022-01-06 |
2023-07-13 |
Vib Vzw |
Improved silage grasses
|
|
WO2023144199A1
(en)
|
2022-01-26 |
2023-08-03 |
Vib Vzw |
Plants having reduced levels of bitter taste metabolites
|
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
EP4658675A1
(en)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Methods for non-viral manufacturing of engineered immune cells
|
|
AU2024255934A1
(en)
|
2023-04-14 |
2025-11-20 |
Precision Biosciences, Inc. |
Muscle-specific expression cassettes
|
|
WO2024216116A1
(en)
|
2023-04-14 |
2024-10-17 |
Precision Biosciences, Inc. |
Muscle-specific expression cassettes
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
WO2024238726A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating methylation of a target gene
|
|
WO2025004001A1
(en)
|
2023-06-30 |
2025-01-02 |
Takeda Pharmaceutical Company Limited |
Htt repressors and uses thereof
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
WO2025194124A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
Modified st1cas9 guide nucleic acids
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|